Website
News25/Ratings12
News · 26 weeks33+14%
2025-10-262026-04-19
Mix2490d
- Insider11(46%)
- SEC Filings7(29%)
- Other4(17%)
- Earnings2(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Murray Katherine4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Anastasio Curt4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Klingensmith Harvey Robert4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Temeng Kwaku4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Martinovich Robert F4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Carnes Martha Z.4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- SECSEC Form DEFA14A filed by Core Laboratories Inc.DEFA14A - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECSEC Form DEF 14A filed by Core Laboratories Inc.DEF 14A - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Core Laboratories Inc.SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
- PRCORE LAB ANNOUNCES IMPACT OF THE MIDDLE EAST CONFLICT TO FIRST QUARTER 2026 GUIDANCEFIRST QUARTER 2026 EARNINGS WEBCAST AT 7:30 A.M. CDT / 8:30 A.M. EDT ON APRIL 30, 2026HOUSTON, March 23, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority.At this time, due to regional instability, including client-driven project delays, travel const
- SECCore Laboratories Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECSEC Form 10-K filed by Core Laboratories Inc.10-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECAmendment: Core Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K/A - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECCore Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECSEC Form NT 10-K filed by Core Laboratories Inc.NT 10-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Core Laboratories Inc.SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
- INSIDERSEC Form 4 filed by SVP, Gen Counsel & Secretary Tattoli Mark Damian4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by SVP Gresham Gwendolyn4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by SVP & CFO Hill Christopher Scott4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Chairman and CEO Bruno Lawrence4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by CAO & Treasurer Teo Sow Hang4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Core Laboratories Inc.SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
- PRCORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTSFOURTH QUARTER REVENUE OF $138.3 MILLION, UP 3% SEQUENTIALLY AND UP 7% YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $15.8 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEARFOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF OVER 11%, DOWN 100 BASIS POINTS SEQUENTIALLY AND 80 BASIS POINTS YEAR-OVER-YEARFOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.21, DOWN 4% SEQUENTIALLY AND YEAR-OVER-YEARFOURTH QUARTER FREE CASH FLOW OF $5.1 MILLIONNET DEBT REDUCED BY $1.2 MILLION; LEVERAGE RATIO IMPROVED TO 1.09COMPANY REPURCHASED 363,207 SHARES OF COMMON STOCK, FOR $5.7 MILLION AGGREGATE PURCHASE PRICECOMPANY ANNOUNCES Q1 2026 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $526.5 MILLI
- SECCore Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- PRCORE LABORATORIES ANNOUNCES TIMING OF FOURTH QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALLHOUSTON, Jan. 5, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2025 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m. EST on February 5, 2026. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on February 4, 2026, and may be accessed through the Company's website at www.corelab.com/investors. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webc